Bcl-xL gain of function and p19 ARF loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms

Andrew Finch, Julia Prescott, Ksenya Shchors, Abigail Hunt, Laura Soucek, Tobias B Dansen, Lamorna Brown Swigart, Gerard I Evan

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Overexpression of Bcl-xL, loss of p19 ARF, and loss of p53 all accelerate Myc oncogenesis. All three lesions are implicated in suppressing Myc-induced apoptosis, suggesting that this is a common mechanism by which they synergize with Myc. However, using an acutely switchable model of Myc-induced tumorigenesis, we demonstrate that each lesion cooperates with Myc in vivo by a distinct mechanism. While Bcl-xL blocks Myc-induced apoptosis, inactivation of p19 ARF enhances it. However, this increase in apoptosis is matched by increased Myc-induced proliferation. p53 inactivation shares features of both lesions, partially suppressing apoptosis while augmenting proliferation. Bcl-xL and p19 ARF loss together synergize to further accelerate Myc oncogenesis. Thus, differing lesions cooperate oncogenically with Myc by discrete mechanisms that can themselves synergize with each other.
Original languageEnglish
Pages (from-to)113-20
Number of pages8
JournalCancer Cell
Volume10
Issue number2
DOIs
Publication statusPublished - Aug 2006

Keywords / Materials (for Non-textual outputs)

  • Animals
  • Apoptosis
  • Tumor Suppressor Protein p53
  • Genes, myc
  • Cyclin-Dependent Kinase Inhibitor p21
  • Mice
  • Cell Proliferation
  • Mice, Transgenic
  • bcl-X Protein
  • Cyclin-Dependent Kinase Inhibitor p16
  • Insulin-Secreting Cells
  • Tumor Suppressor Protein p14ARF
  • Cell Transformation, Neoplastic

Fingerprint

Dive into the research topics of 'Bcl-xL gain of function and p19 ARF loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms'. Together they form a unique fingerprint.

Cite this